PulseAugur
EN
LIVE 19:47:47

Noetik licenses AI models to GSK for $50M to improve cancer trial success rates

By PulseAugur Editorial · [2 sources] ·

Noetik, a biotech company, is leveraging AI, specifically transformer models like TARIO-2, to address the high failure rate in cancer clinical trials. Their approach focuses on better matching patients with specific tumor types to existing treatments, rather than discovering new drugs. This strategy has led to a significant $50 million deal with GSK, marking a shift towards licensing AI platforms rather than developing drugs directly. AI

RANK_REASON Biotech company secures a $50M deal with a major pharmaceutical firm for its AI platform.

Read on Latent Space Podcast →

AI-generated summary · Google Gemini · from 2 sources. How we write summaries →

Noetik licenses AI models to GSK for $50M to improve cancer trial success rates

How we ranked this

Signal score
0 / 100
Composite score across the factors below. Higher = stronger signal that this story matters right now.
Newsworthiness bucket
Significant
Biotech company secures a $50M deal with a major pharmaceutical firm for its AI platform.
Source corroboration
2 independent sources
Multiple independent publishers reporting the same story raises confidence that it's real and newsworthy.
Topics
model release, product, funding
Editorial topic classification. Feeds into how the story surfaces on /topic/<slug> hub pages and into the per-entity coverage mix.
AI-industry relevance
High
Clearly on-topic for AI-industry coverage.
Story freshness
159 days old
Aged out of breaking-news scoring windows; ranking reflects the durable signal from the full source set.

Full methodology in our editorial standards.

COVERAGE [2]

  1. Latent Space Podcast TIER_1 English(EN) · Brandon Anderson, RJ Honicky, and Latent.Space ·

    🔬 Training Transformers to solve 95% failure rate of Cancer Trials — Ron Alfa & Daniel Bear, Noetik

    <p>Today, we explain this piece of “clickbait” from our guest!</p><p><strong>TL;DR: 95% of cancer treatments fail to </strong><a href="https://www.nature.com/articles/s41467-025-64552-2" target="_blank"><strong>pass clinical trials</strong></a><strong>, but it may be a matching p…

  2. Latent Space (podcast video) TIER_1 English(EN) · Latent Space ·

    🔬 Training Transformers to solve 95% failure rate of Cancer Trials — Ron Alfa & Daniel Bear, Noetik

    TL;DR: 95% of cancer treatments fail to pass clinical trials, but it may be a matching problem — if we better understood what patients have which tumors which will respond to which treatments, success rates improve dramatically and millions of lives can be saved — with the treatm…

RELATED ENTITIES

RELATED TOPICS